Resistance looms for KRAS^G12C inhibitors

Nat Med. 2020 Feb;26(2):169-170. doi: 10.1038/s41591-020-0765-z.

Authors

Aaron N Hata¹, Alice T Shaw²

Affiliations

¹ Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. ahata@mgh.harvard.edu.
² Novartis Institutes of Biomedical Research, Cambridge, MA, USA. ashaw1@mgh.harvard.edu.

PMID: 32020086
DOI: 10.1038/s41591-020-0765-z

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Humans
Lung Neoplasms*
Proto-Oncogene Proteins p21(ras)

Substances

Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins p21(ras)